

Recurrent gross mutations of the *PTEN* tumor suppressor gene in breast cancers with deficient DSB repair

Lao H Saal^{1,2}, Sofia K Gruvberger-Saal¹, Camilla Persson³, Kristina Lövgren³, Mervi Jumppanen^{4,5}, Johan Staaf³, Göran Jönsson³, Maira M Pires⁶, Matthew Maurer^{1,7}, Karolina Holm³, Susan Koujak¹, Shivakumar Subramaniyam⁸, Johan Vallon-Christersson³, Håkan Olsson³, Tao Su⁹, Lorenzo Memeo¹⁰, Thomas Ludwig^{1,8}, Stephen P Ethier¹¹, Morten Krogh¹², Matthias Szabolcs⁸, Vundavalli VVS Murty^{1,8}, Jorma Isola⁵, Hanina Hibshoosh^{8,9}, Ramon Parsons^{1,7-9,14} & Åke Borg^{3,13,14}

Basal-like breast cancer (BBC) is a subtype of breast cancer with poor prognosis¹⁻³. Inherited mutations of *BRCA1*, a cancer susceptibility gene involved in double-strand DNA break (DSB) repair, lead to breast cancers that are nearly always of the BBC subtype³⁻⁵; however, the precise molecular lesions and oncogenic consequences of *BRCA1* dysfunction are poorly understood. Here we show that heterozygous inactivation of the tumor suppressor gene *Pten* leads to the formation of basal-like mammary tumors in mice, and that loss of *PTEN* expression is significantly associated with the BBC subtype in human sporadic and *BRCA1*-associated hereditary breast cancers. In addition, we identify frequent gross *PTEN* mutations, involving intragenic chromosome breaks, inversions, deletions and micro copy number aberrations, specifically in *BRCA1*-deficient tumors. These data provide an example of a specific and recurrent oncogenic consequence of *BRCA1*-dependent dysfunction in DNA repair and provide insight into the pathogenesis of BBC with therapeutic implications. These findings also argue that obtaining an accurate census of genes mutated in cancer will require a systematic examination for gross gene rearrangements, particularly in tumors with deficient DSB repair.

Advances in methodologies for high-throughput DNA sequencing and copy number analysis have hastened the global cataloguing of genetic abnormalities in cancer (for example, see refs. 6–8). Although such studies have identified classical coding mutations and large amplifications and deletions in known and putative oncogenes and tumor suppressors, some types of genetic change, such as chromosome breaks, gene translocations and microduplications or microdeletions,

are difficult to detect. Indeed, recurrent fusions between *TMPRSS2* and *ETS* family transcription factor genes have been identified in prostate carcinoma by a systems biology approach⁹, and they suggest that oncogenic gene rearrangements may be common in epithelial neoplasia. Global gene expression profiling studies of breast carcinoma have delineated several molecular subtypes that have distinct pathological and clinical characteristics¹⁻⁵. Of these, basal-like breast cancer (BBC) comprises 10–20% of all breast cancer and is one of the subtypes with the worst prognosis²⁻⁵. The term BBC was coined because these tumors express cytokeratin markers typical of basally oriented epithelial cells of the normal mammary gland, such as CK5, CK14 and CK17 (refs. 1,3,5). In addition to having characteristic cytokeratin expression, BBCs are highly proliferative, poorly differentiated and genomically unstable, and they pose clinical challenges because they rarely express the three most common therapeutically targeted ‘Achilles’ heels’ of breast cancer: the estrogen receptor (ER), progesterone receptor and HER2 receptor (refs. 1,3,5,7).

Intriguingly, breast tumors initiated by an inherited mutation of *BRCA1* are nearly always basal-like^{3,5}. *BRCA1* dysfunction is thought to be tumorigenic primarily owing to defective *BRCA1*-dependent DSB repair, which precipitates an accumulation of secondary mutations¹⁰; however, only general genomic patterns at relatively low resolution have been described (reviewed in ref. 5). Despite these advances in delineating BBC, the molecular lesions and oncogenic signaling pathways that drive BBC and the precise oncogenic consequences of *BRCA1*-mediated basal-like tumorigenesis are incompletely known. The phosphatidylinositol 3-kinase (PI3K) pathway is a potent oncogenic signaling cascade that promotes cell transformation, proliferation, migration, angiogenesis and genomic instability; inhibits apoptosis; maintains stem cell compartments; and is associated with

¹Institute for Cancer Genetics and ²College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA. ³Division of Oncology, Department of Clinical Sciences, Lund University, 22185 Lund, Sweden. ⁴Department of Pathology, Seinäjoki Central Hospital, 60220 Seinäjoki, Finland. ⁵Institute of Medical Technology, University of Tampere, 33014 Tampere, Finland. ⁶Department of Biochemistry, ⁷Department of Medicine, ⁸Department of Pathology, and ⁹Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA. ¹⁰Pathology Unit, Mediterranean Institute of Oncology, 95029 Catania, Italy. ¹¹Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA. ¹²Computational Biology and Biological Physics, Department of Theoretical Physics, Lund University, 22362 Lund, Sweden. ¹³Lund Strategic Center for Stem Cell Biology and Cell Therapy, Lund University, 22185 Lund, Sweden. ¹⁴These authors contributed equally to this work. Correspondence should be addressed to R.P. (rep15@columbia.edu).

Received 30 July; accepted 16 October; published online 9 December 2007; doi:10.1038/ng.2007.39






Figure 1 IHC analysis of basal-like phenotype markers in *Pten*^{+/-} mouse mammary tumors. **(a)** Representative section showing IHC staining for CK5/6, CK14 and ER in a *Pten*^{+/-} mammary tumor (top) and normal breast tissue from a wild-type (*Pten*^{+/+}) control mouse (bottom). Arrows indicate tumor cells; filled arrowheads indicate non-neoplastic basal-layer epithelial cells; open arrowhead indicates non-neoplastic luminal-layer epithelial cells. Scale bars, 25 μ m. **(b)** CK5/6/14 IHC staining scores for 13 *Pten*^{+/-} mammary tumors. The maximal score for CK5/6 or CK14 staining (Methods) is plotted for each tumor compartment; a score of 1+ (horizontal broken line) is defined as basal-like. 0, tumor compartment present but no staining; np, respective component not present in tumor. See also **Supplementary Table 1** online.

poor prognosis in carcinoma^{11–14}. PTEN is the crucial tumor suppressor in this pathway because it catalyzes the precise opposite reaction to PI3K, thereby inhibiting downstream signaling¹². In breast cancer, documented coding mutations of *PTEN* are rare (<5%); however, ~25% of tumors have significantly diminished amounts of PTEN protein, resulting in unrestrained signaling by the PI3K pathway¹⁵.

While reviewing breast cancer subtypes in mouse models, we noted that all 13 mammary tumors derived from 12 mice with heterozygous inactivation of one *Pten* allele¹⁶ showed basal-like characteristics (positive staining for CK5, CK6 or CK14 (hereafter CK5/6/14) by immunohistochemistry (IHC); **Fig. 1** and **Supplementary Table 1** online). To investigate the role of PTEN in human BBC, we therefore characterized PTEN and CK5/14 protein expression by IHC in non-hereditary breast tumors from 297 individuals (**Fig. 2a**). A reduction in PTEN protein immunostaining (PTEN^{IHC-loss}) of tumor cells as compared with adjacent non-neoplastic cells was observed significantly more frequently in CK5/14-positive BBC than in CK5/14-negative non-BBC (54.3 versus 13.4%, respectively; $P = 4 \times 10^{-9}$; **Fig. 2b** and **Supplementary Table 2** online). Because both the BBC phenotype^{1,3,5} and reduced PTEN¹⁵ have been associated with lack of ER expression, we tested the relationship between PTEN and basal-like status in the ER-negative subset and found that it remained significant (56.3 versus 29.1%; $P = 0.0122$; **Fig. 2b** and **Supplementary Table 2** online). Loss of PTEN thus defines a significant subset of non-hereditary BBC (NHBBC).

Given that nearly all *BRCA1*-associated hereditary breast cancers are basal-like^{3,5,17}, we next investigated PTEN expression in 34 breast tumor biopsies from individuals with inherited *BRCA1* mutations (hereditary BBC (HBBC); **Supplementary Table 3** online). Notably, 82.4% (28/34) of tumors showed loss of PTEN by IHC ($P = 4 \times 10^{-12}$; **Fig. 3a**). In addition, suggestive of a genetic mechanism for PTEN loss, 52.9% (18/34) of tumors showed a marked staining pattern; namely, PTEN protein was completely undetectable in tumor cells (PTEN^{IHC-null}) but strongly expressed in adjacent normal cells (**Fig. 3a–c,e**). To test for an association between the PTEN^{IHC-null} phenotype and mutation of *PTEN*, we screened 14 PTEN^{IHC-null} non-hereditary breast tumors (**Fig. 3d**) and 8 PTEN^{IHC-null} HBBC tumors (**Fig. 3a–c**) for mutations in *PTEN* by DNA sequencing. Whereas half of the PTEN^{IHC-null} non-hereditary tumors had coding mutations in *PTEN*, unexpectedly, no sequence alterations were found

in the HBBC samples ($P = 0.0154$; **Fig. 3f**). These results, together with the fact that the HCC-1937 *BRCA1*-mutant cell line is known to have homozygous deletion of *PTEN*¹⁸, suggested that *BRCA1*-mutant tumors may have a distinct type of *PTEN* genetic lesion.

To investigate this possibility, we examined two model breast cancer cell lines, MDA-MB-436 and SUM-149, that are known to have mutations in *BRCA1* (ref. 19) and to be basal-like²⁰. These cell lines are ideal models because both carry the wild-type *PTEN* gene, as determined by DNA sequencing, but neither expresses PTEN protein, as assessed by protein blotting. In addition, PTEN expression cannot be induced by treatment with demethylation agents, indicating that PTEN silencing is not due to promoter methylation (data not shown). Conventional tiling BAC array comparative genomic hybridization (aCGH) experiments (data not shown) indicated




Figure 2 Immunohistochemical analysis of PTEN and CK5/14 basal-like phenotype markers in 297 non-hereditary human breast carcinomas. **(a)** Representative PTEN and CK5/14 IHC in two non-hereditary breast tumors. Top, a PTEN^{IHC-positive} and CK5/14-negative example; bottom, a PTEN^{IHC-loss} and CK5/14-positive example. Arrows indicate tumor cells; arrowheads indicate non-neoplastic cells. Asterix denotes the non-neoplastic CK5/14-positive basal epithelial layer enclosing a portion of *in situ* breast carcinoma, shown here as an example of an internal positive control. Scale bars, 25 μ m. **(b)** Correlation analysis between PTEN loss and the CK5/14-positive basal-like subtype among all tumors (left) and in the ER-negative group (right). * $P = 0.0122$; ** $P = 4 \times 10^{-9}$.




Figure 3 PTEN status in human *BRCA1*-mutant hereditary breast cancers. (**a–d**) PTEN IHC results for three representative PTEN^{IHC-null} *BRCA1*-associated hereditary breast tumor specimens (**a–c**) and one non-hereditary PTEN^{IHC-null} breast tumor with a *PTEN* fs108X mutation (**d**). Scale bars, 25 μ m. (**e**) Fraction of PTEN^{IHC-loss} (filled) and PTEN^{IHC-null} (open) tumors among 34 *BRCA1*-associated hereditary breast tumors. (**f**) Analysis of *PTEN* nucleotide sequence mutations in PTEN^{IHC-null} non-hereditary breast cancers versus PTEN^{IHC-null} *BRCA1*-mutant hereditary breast cancers.

that both cell lines show DNA copy number loss at the *PTEN* locus on chromosome 10q23.31, consistent with loss of one allele (loss of heterozygosity; LOH).

To look for smaller genetic lesions, we used a custom-designed high-density oligonucleotide aCGH (HD-aCGH) platform containing 1,747 probes spanning a region of ~ 500 kb centered on *PTEN* with an average interprobe spacing of 288 bp. HD-aCGH analysis showed that these regions of apparent *PTEN* LOH in fact contained highly focal, intragenic copy number increases (CNIs) in *PTEN*, affecting a portion of intron 2 (MDA-MB-436) and spanning exon 2 (SUM-149; **Fig. 4a,b**). Given the role of *BRCA1* in DSB repair, we considered

that the intragenic *PTEN* CNIs may be associated with gross chromosomal rearrangements. We therefore designed a two-color FISH assay (**Fig. 4c**) and identified distinct rearrangements of chromosome 10 that physically split the single remaining *PTEN* allele in each cell line (**Fig. 4d**). These results were corroborated for both cell lines by 5'-to-3' exon-walking using RT-PCR, by which we could not amplify specific *PTEN* transcripts beyond exon 2 (data not shown). These data are most consistent with a mechanism involving multiple DSBs and inappropriate repair and reduplication of DNA segments at or near the breakpoints.

To investigate further the association of these types of *PTEN* locus structural mutation (hereafter termed 'gross' *PTEN* mutations; GPMs) with *BRCA1* status, we sequenced *BRCA1* in three breast cancer xenografts with identified homozygous deletions of *PTEN*²¹ (**Table 1**, **Supplementary Table 3** and **Supplementary Fig. 1** online). One xenograft, MX-1 (also known as Bx11),

was found to have the 2795del4 *BRCA1* mutation. (Although matched normal DNA was not available, this mutation is likely to be germ line because 2795del4 is a known *BRCA1* founder mutation and the xenograft was established from a 29-year-old individual²².) Next, to test the relationship between *BRCA1* and GPM rigorously, we selected all breast cancer cell lines and xenografts with any type of *PTEN* mutation from 31 samples that were comprehensively annotated for *BRCA1* and *PTEN* mutational status (all cell lines positive for *PTEN* protein by protein blotting were assumed to not have GPMs; **Table 1**). Among the 13 samples with any type of *PTEN* mutation, GPMs were significantly associated with




Figure 4 Gross *PTEN* mutations in *BRCA1*-mutant human cell lines and xenografts. (**a,b**) HD-aCGH analyses of two model *BRCA1*-mutant breast cancer cell lines. The location of *PTEN* exons 1–9 on chromosome 10q23.31 are indicated by blue bars. The \log_2 ratios for probes localized in the *PTEN* gene are plotted in red; those for all other probes are plotted in black (gaps with no probes are present in several regions that contain highly repetitive sequence elements such as intron 2). Arrows indicate regions of focal CNI. Prominent broken horizontal lines are placed at \log_2 ratios of 0.3 and -0.3 . (**c**) Two-color FISH assay. The *PTEN* gene and exons are indicated in blue. Centromeric BAC probes were labeled with spectrum orange-dUTP (red); telomeric BAC probes were labeled with spectrum green-dUTP (green). (**d**) FISH results for the *BRCA1*-mutant breast cancer cell lines in **a,b**. Inset, representative FISH results for one chromosome of a normal lymphocyte metaphase spread. (**e**) Analysis of *BRCA1* mutation (mt) and GPM among 13 breast cancer xenografts and cell lines with any type of *PTEN* mutation. The basal-like status of these cell lines and xenografts is given in **Table 1**.

Table 1 *BRCA1* and *PTEN* status in 31 breast cancer cell lines and xenografts

Sample ID	<i>BRCA1</i> mutation status ^a	<i>PTEN</i> mutation status	<i>PTEN</i> protein blot	Subtype ^b
HCC-1937	5382insC (fs>1829X)	GPM (HD)	Null	Basal-like
MDA-MB-436	5396+1G>A (splice donor)	GPM (micro-CNI)	Null	Basal-like
MX-1 ^c	2795delT (fs>999X)	GPM (HD)	n.d.	n.a.
SUM-149	2288delT (fs>735X)	GPM (micro-CNI)	Null	Basal-like
BT-549	WT	822delG (L295X)	Null	Basal-like
Bx15 ^c	WT	GPM (HD)	n.d.	n.a.
Bx33 ^c	WT	GPM (HD)	n.d.	n.a.
CAMA-1	WT	274G>C (D92H)	Positive	Luminal
EWSA-T	WT	951del4 (T319X)	n.d.	n.a.
MDA-MB-415	WT	407G>A (C136Y)	Positive	Luminal
MDA-MB-453	WT	919G>A (E307K)	Positive	Luminal
MDA-MB-468	WT	IVS4+1G>T (A72fsX5)	Null	Basal-like
ZR75-1	WT	323T>G (L108R)	Positive	Luminal
BT-20	WT	WT	Positive	Basal-like
BT-474	WT	WT	Positive	Luminal
BT-483	WT	WT	Positive	Luminal
DU-4475	WT	WT	Positive	n.a.
Hs578T	WT	WT	Positive	Basal-like
MCF-7	WT	WT	Positive	Luminal
MDA-MB-134VI	WT	WT	Positive	Luminal
MDA-MB-157	WT	WT	Positive	Basal-like
MDA-MB-175VII	WT	WT	Positive	Luminal
MDA-MB-231	WT	WT	Positive	Basal-like
MDA-MB-361	WT	WT	Positive	Luminal
MDA-MB-435S	WT	WT	Positive	Basal-like
SK-BR-3	WT	WT	Positive	Luminal
SUM-159PT	WT	WT	Positive	Basal-like
T-47D	WT	WT	Positive	Luminal
UACC-812	WT	WT	Positive	Luminal
UACC-893	WT	WT	Positive	n.a.
ZR75-30	WT	WT	Positive	Luminal

All mutations are relative to the +1 adenine nucleotide of the ATG start codon, with the amino acid change given in parentheses. GPM, gross *PTEN* mutation; HD, homozygous deletion; CNI, DNA copy number increase; n.d., not done; n.a., not available.

^aFor cell line samples, *BRCA1* mutational status is taken from ref. 19. ^bBreast cancer subtype is taken from ref. 20. ^cXenograft.

mutations in *BRCA1*; by contrast, *PTEN* coding mutations were specifically associated with wild-type *BRCA1* ($P = 0.0210$; **Fig. 4e**). We therefore conclude that *BRCA1* dysfunction is associated with GPM.

These results were corroborated in breast tumor biopsies from women with hereditary *BRCA1* mutations. Of 17 HBBC tumors analyzed for conventional *PTEN* mutations by DNA sequencing, all had wild-type *PTEN* (**Supplementary Table 3** online). When analyzed on the HD-aCGH platform, however, five (71.4%) of seven *PTEN*^{IHC-null} HBBC tumors had specific GPMs associated with micro-CNIs ($n = 2$), macro-CNI ($n = 1$) and homozygous deletions ($n = 2$; **Fig. 5a–e**, **Supplementary Table 3** and **Supplementary Fig. 1** online). Seven of these HBBC samples, in addition to one *PTEN*^{IHC-loss} and three *PTEN*^{IHC-positive} HBBC tumors, were also analyzed on the conventional BAC aCGH platform (data not shown). Indicating the increased sensitivity of the HD-aCGH platform for detecting GPMs, one homozygous deletion was difficult to discern and both micro-CNIs were undetectable by BAC aCGH (data not shown). In addition, beyond copy number loss consistent with LOH, no obvious GPMs were detected in the *PTEN*^{IHC-loss} or *PTEN*^{IHC-positive} HBBCs.

Combining our patient tumor data with our data from cell lines and xenografts, we analyzed in total 28 *BRCA1*-mutant samples by

conventional BAC aCGH, custom HD-aCGH and/or conventional DNA sequencing, and found nine cancers (32.1%) with GPMs. We conclude that *PTEN* loss is highly associated with both NHBBC and HBBC and can result from gene rearrangements involving DNA DSBs, intragenic inversions or insertions, homozygous deletions and focalized CNIs. Because chromosomal breaks, CNIs and small microdeletions were not detected by conventional aCGH or DNA sequencing, we are probably underestimating the true rate of GPMs in HBCC. Indeed, our *PTEN*^{IHC-null} data would suggest a rate of more than 50%. In addition, we identified two NHBBC samples with homozygous deletion of *PTEN* and, notably, both had hypermethylation of the *BRCA1* promoter (data not shown), suggesting that *BRCA1*-dependent *PTEN* disruption may also occur in some sporadic breast tumors.

Our results have important implications for the pathogenesis and treatment of BBC and raise significant considerations for future mutation-cataloguing efforts in disease. The basal-like phenotype of *Pten*^{+/-} mammary tumors and the high rate of *PTEN* loss in NHBBC and HBBC imply that the *PTEN* pathway is directly involved in transformation of basal-like progenitor cells. Notably, conventional sequence mutations of the *TP53* tumor suppressor gene occur in >80% of NHBBC and HBBC (reviewed in ref. 5). Together, our results suggest that all three tumor suppressors are inactivated in a considerable proportion of BBC. Although the spectrum of *TP53* mutations seems to differ between non-hereditary and hereditary breast cancer²³, the observed mutational profiles of

TP53 are not as specific or as markedly divergent as we have found here for *PTEN*, indicating that the selective pressure and/or mutational mechanism on *TP53* and *PTEN* are likely to be distinct. Our data are most consistent with a model of HBBC oncogenesis in which selected stochastic coding mutation of *TP53* in a basal-like breast cancer progenitor cell precedes loss of the second *BRCA1* allele, which is known to otherwise be lethal to cells (reviewed in ref. 24), and that the subsequent *BRCA1*-dependent DSB repair defect precipitates genetic disruption of *PTEN*, which is then clonally selected. This model implies that most BBCs may be addicted²⁵ to aberrant *PTEN*-PI3K pathway signaling. As a result, therapy targeted to this pathway may be an effective way to treat and possibly to prevent some sporadic and hereditary BBC.

Our study demonstrates an example of a specific and recurrent oncogenic consequence of defective DSB repair in breast cancer, and it is possible that other grossly rearranged genes also contribute to tumor progression. Our observations in HBBC are analogous to those in hereditary nonpolyposis colon cancer, where microsatellite instability due to lack of mismatch repair leads to mutation of *TGFBR2* and other genes that drive tumor progression²⁶. Our results highlight the need for high-throughput genomic methods to screen for gross structural gene mutations at a sub-kilobase resolution. There may be a wealth of gross mutations




Figure 5 Gross *PTEN* mutations in five *BRCA1*-mutant breast tumor biopsies *in vivo*. (**a–e**) Analysis of $PTEN^{IHC-null}$ *BRCA1*-associated breast tumors by HD-aCGH, revealing *PTEN* homozygous deletions (**a,e**), macro-CNI (**b**) and micro-CNIs (**c,d**). Probes and the *PTEN* locus are plotted as in **Figure 4a,b**. Green bars indicate neighboring genes.

annotated Ensembl v36 *BRCA1* genomic sequence): *BRCA1* region 1, –1291 to –1267 (containing five CpGs); and region 2, –1332 to –1310 (four CpGs). We used the following primers: *BRCA1*_Region1/2_PCR_F, 5'-NNTATTTTGGAGAGGTTGTGTTTAG-3'; *BRCA1*_Region1/2_PCR_R, 5'-biotin-TAA AAAACCCACAACTATCC-3'; *BRCA1*_Region1_Seq, 5'-GAATTATAGATAAATTA-3'; and *BRCA1*_Region2_Seq, 5'-GGTAGTTTTTGGTTT T-3'. In all runs, CpGenome Universal Methylated DNA (Chemicon) was analyzed as a positive control, and CpGenome Universal Unmethylated DNA and reactions with no DNA were used as negative controls.

DNA sequencing. *PTEN* exons including intronic boundaries were sequenced as described¹⁵. *BRCA1* mutations were identified by standard techniques²⁷.

in breast cancer and other types of carcinoma in which such changes were once thought to be rare.

METHODS

Human tumor samples and immunohistochemistry. All tumor specimens were studied after approval by the Lund University Hospital ethics committee and Columbia University Institutional Review Board. Tissue microarrays containing formalin-fixed paraffin-embedded tissues in replicates from 425 individuals diagnosed with stage II invasive breast cancer but without a significant family history of breast or ovarian cancer were subjected to IHC staining for CK5/14. CK5/14 IHC was performed and scored into CK5/14-positive (defining basal-like status) and CK5/14-negative groups as described¹⁷. Some of these individuals were evaluated for *PTEN* protein expression by IHC on whole-mount, formalin-fixed, paraffin-embedded tissue sections, and the tumors were scored as *PTEN*-positive ($PTEN^{IHC-positive}$) or *PTEN*-loss ($PTEN^{IHC-loss}$) relative to normal epithelial, endothelial and/or stromal cells in each tissue section as described¹⁵. Tumors with undetectable *PTEN* immunostaining in contrast to adjacent normal cells were scored as *PTEN*-null ($PTEN^{IHC-null}$). We analyzed 297 tumors for both *PTEN* and CK5/14. Thirty-four breast tumors from carriers of germline *BRCA1* mutations were obtained for *PTEN* IHC and genetic analyses. *PTEN* IHC was performed and scored for these tumors as above, with the exception that the primary antibody to *PTEN* was monoclonal (138G6, Cell Signaling Technology; dilution, 1:200; incubation, 2 h), and the Dako EnVision Plus system was used for signal detection.

Cell lines and xenografts. Breast cancer cell lines were obtained from the American Type Culture Collection and S. Ethier and were cultured according to standard recommendations. The MX-1 (also known as Bx11), Bx15 and Bx33 breast cancer xenografts have been described²¹. *PTEN* protein blotting was performed as described¹⁴.

***BRCA1* promoter hypermethylation.** *BRCA1* promoter region methylation was analyzed by using a PSQ HS 96 pyrosequencing system according to manufacturer protocols (Biotage). DNA was isolated with a Wizard Genomic DNA purification kit (Promega) and bisulfate-modified with a EZ DNA Methylation kit (Zymo Research). We designed an assay containing two CpG island regions with internal controls for bisulfite treatment (nucleotide positions are relative to the +1 adenine of the ATG translational start codon on the

aCGH. Experiments using the 32K BAC aCGH platform were performed by using described methods²⁸. A custom-designed HD-aCGH microarray (Agilent) was also used as described²⁹. In brief, this HD-aCGH microarray contains 1,747 probes in replicates covering a region of ~500 kb centered on the *PTEN* locus at a mean spacing of 288 bp, and an additional ~20,000 probes with wide genome coverage that are used for data normalization with the popLowess algorithm²⁹. Labeling and hybridization were performed according to the manufacturer's recommendations, and data were loaded into BASE³⁰ for analysis.

Two-color split-probe FISH. The following BACs were obtained from the BACPAC Resource Center (Children's Hospital Oakland Research Institute) or Invitrogen, and DNA was prepared by standard techniques: RP11-1036I20, RP11-57C13, RP11-210E13, RP11-79A15, RP11-765C10, CTD-2243A23, RP11-959L24 and RP11-762G5. The RP11-1036I20, RP11-57C13, RP11-210E13 and RP11-79A15 probes 5' to *PTEN* were generated by nick translation and labeled with spectrum orange dUTP; the RP11-765C10, CTD-2243A23, RP11-959L24, RP11-762G5 probes 3' to *PTEN* were labeled with spectrum green dUTP. Metaphase chromosome spreads were prepared, and FISH was carried out by standard methods; hybridization signals were scored on at least 20 metaphase spreads.

***Pten*^{+/-} mouse mammary tumors.** The *Pten*^{+/-} mouse has been described¹⁶. Mouse research was approved by the Columbia Animal Care and Use Committee. Female mice developed mammary tumors at an average age of 11 months. Thirteen tumors from 12 mice were collected, fixed in formalin and embedded in paraffin. For IHC, primary antibodies D5/16 B4 (monoclonal antibody to CK5 or CK6 (anti-CK5/6); Covance) and AF64 (polyclonal anti-CK14; Covance) were used at 1:500 dilution and SC542 (polyclonal anti-ER; Santa Cruz) was used at 1:400 dilution after microwave antigen retrieval in 0.01 M citrate buffer. D5/16 B4 was applied overnight at 4 °C, whereas AF64 and SC542 were applied for 1 h at 22 °C. A Vectastain kit (Vector Labs) was used to detect binding of the primary antibody to its target antigen in accordance with the manufacturer's recommendation using 3,3'-diaminobenzidine for visualization. Cytokeratin immunostaining was scored as follows: 0, no staining; 1+, moderate staining; 2+, focally strong (<15% of cells); 3+, strong in >15% of cells. CK5/6/14-positive was defined as 1+ (one case), 2+ (two cases) or 3+ (ten cases) for CK5/6 or CK14 staining in either the gland-forming tumor epithelial cell or

metaplastic tumor epithelial cell compartments. IHC staining of ER was scored as follows: 0, <1% positive nuclei; 1+, 1–4% positive nuclei; 2+, ≥5% positive nuclei.

Statistical analyses. Correlations between variables in 2×2 tables were assessed with Pearson's χ^2 test, and tables with cells with fewer than five observations were assessed with Fisher's exact test (sum of small P values). Tests were two-sided, and a P value of <0.05 was considered significant. Assuming a 25% prior probability rate (the approximate rate of PTEN loss in breast cancer), a one-sided P value for PTEN protein loss in BRCA1-associated hereditary breast cancer was calculated as the probability of having 28 or more PTEN^{IHC-loss} samples out of 34 cases with a binomial distribution.

Note: Supplementary information is available on the Nature Genetics website.

ACKNOWLEDGMENTS

We thank the patients whose contributions made this work possible. We thank B. Giovannella (Stehlin Foundation for Cancer Research) for breast cancer xenografts; J. Valcich, L. Tellhed and C. Strand for technical support; and R. Szalaszny for administrative assistance. We regret our inability to cite all references germane to this work owing to space limitations. Funding was provided in part by US National Institutes of Health Scientist training grant 5T32 GM07367-29 (L.H.S.); grants CA082783 and CA097403 (R.P.); Department of Defense Breast Cancer Research Program Era of Hope Award BC061955 (S.K.G.-S.); the Avon Foundation (H.H., R.P.); the OctoberWoman Foundation (R.P.); the Swedish Cancer Society, Mrs. Berta Kamprad Foundation, Gunnar Nilsson Cancer Foundation, and Ingabritt and Arne Lundberg Foundation (Å.B.); and the Knut and Alice Wallenberg Foundation via the SWEGENE program (M.K., Å.B.).

AUTHOR CONTRIBUTIONS

L.H.S., S.K.G.-S., R.P. and Å.B. conceived and designed the study; L.H.S., S.K.G.-S., J.S., G.J., K.H., S.K., J.V.-C., H.O., T.S., L.M., S.P.E., H.H., R.P. and Å.B. collected the samples; L.H.S., K.L., M.J., L.M., T.L., M.S., J.I. and H.H. performed and analyzed immunohistochemistry experiments; L.H.S. and C.P. designed and performed methylation analyses; L.H.S., C.P., M.M. and K.H. performed nucleotide sequencing experiments; L.H.S., J.S., G.J. and K.H. performed and analyzed aCGH experiments; L.H.S., M.M.P., S.S. and V.V.V.S.M. designed and performed FISH experiments; L.H.S., S.K.G.-S. and M.K. performed statistical analyses; R.P. and Å.B. supervised the study; and L.H.S. wrote the paper with assistance from R.P. and Å.B. and input from all coauthors.

Published online at <http://www.nature.com/naturegenetics>

Reprints and permissions information is available online at <http://npg.nature.com/reprintsandpermissions>

- Perou, C.M. *et al.* Molecular portraits of human breast tumours. *Nature* **406**, 747–752 (2000).
- Sorlie, T. *et al.* Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl. Acad. Sci. USA* **98**, 10869–10874 (2001).
- Silva, L.D., Clarke, C. & Lakhani, S.R. Basal-like breast cancer. *J. Clin. Pathol.* doi:10.1136/jcp.2006.041731 (published online 11 May 2007).
- Sorlie, T. *et al.* Repeated observation of breast tumor subtypes in independent gene expression data sets. *Proc. Natl. Acad. Sci. USA* **100**, 8418–8423 (2003).
- Turner, N.C. & Reis-Filho, J.S. Basal-like breast cancer and the BRCA1 phenotype. *Oncogene* **25**, 5846–5853 (2006).
- Sjoberg, T. *et al.* The consensus coding sequences of human breast and colorectal cancers. *Science* **314**, 268–274 (2006).
- Chin, K. *et al.* Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. *Cancer Cell* **10**, 529–541 (2006).
- Greenman, C. *et al.* Patterns of somatic mutation in human cancer genomes. *Nature* **446**, 153–158 (2007).
- Tomlins, S.A. *et al.* Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* **310**, 644–648 (2005).
- Jasin, M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. *Oncogene* **21**, 8981–8993 (2002).
- Puc, J. *et al.* Lack of PTEN sequesters CHK1 and initiates genetic instability. *Cancer Cell* **7**, 193–204 (2005).
- Baker, S.J. PTEN enters the nuclear age. *Cell* **128**, 25–28 (2007).
- Janzen, V. & Scadden, D.T. Stem cells: good, bad and reformable. *Nature* **441**, 418–419 (2006).
- Saal, L.H. *et al.* Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. *Proc. Natl. Acad. Sci. USA* **104**, 7564–7569 (2007).
- Saal, L.H. *et al.* PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res.* **65**, 2554–2559 (2005).
- Podsypanina, K. *et al.* Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc. Natl. Acad. Sci. USA* **96**, 1563–1568 (1999).
- Laakso, M., Loman, N., Borg, A. & Isola, J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. *Mod. Pathol.* **18**, 1321–1328 (2005).
- Tomlinson, G.E. *et al.* Characterization of a breast cancer cell line derived from a germline BRCA1 mutation carrier. *Cancer Res.* **58**, 3237–3242 (1998).
- Elstrodt, F. *et al.* BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. *Cancer Res.* **66**, 41–45 (2006).
- Neve, R.M. *et al.* A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515–527 (2006).
- Li, J. *et al.* PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* **275**, 1943–1947 (1997).
- Giovannella, B.C., Stehlin, J.S. & Williams, L.J. Jr. Heterotransplantation of human malignant tumors in 'nude' thymusless mice. II. Malignant tumors induced by injection of cell cultures derived from human solid tumors. *J. Natl. Cancer Inst.* **52**, 921–930 (1974).
- Greenblatt, M.S., Chappuis, P.O., Bond, J.P., Hamel, N. & Foulkes, W.D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. *Cancer Res.* **61**, 4092–4097 (2001).
- Evers, B. & Jonkers, J. Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. *Oncogene* **25**, 5885–5897 (2006).
- Weinstein, I.B. Cancer. Addiction to oncogenes—the Achilles heel of cancer. *Science* **297**, 63–64 (2002).
- Markowitz, S. *et al.* Inactivation of the type II TGF- β receptor in colon cancer cells with microsatellite instability. *Science* **268**, 1336–1338 (1995).
- Loman, N., Johannsson, O., Kristofferson, U., Olsson, H. & Borg, A. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. *J. Natl. Cancer Inst.* **93**, 1215–1223 (2001).
- Jonsson, G. *et al.* High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. *Genes Chromosom. Cancer* **46**, 543–558 (2007).
- Staaf, J. *et al.* Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2 and MLH1 using zoom-in array CGH. *Hum. Mutat.* (in the press).
- Saal, L.H. *et al.* BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. *Genome Biol.* **3** SOFTWARE0003 (2002).